Published in Diabetes Care on June 01, 2006
Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care (2012) 21.62
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia (2008) 4.62
American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. Endocr Pract (2013) 2.97
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care (2012) 2.89
Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ (2009) 2.69
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab (2012) 2.23
Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes Care (2014) 2.04
Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care (2012) 1.73
Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol (2007) 1.66
Utilization of a Cloud-Based Diabetes Management Program for Insulin Initiation and Titration Enables Collaborative Decision Making Between Healthcare Providers and Patients. Diabetes Technol Ther (2015) 1.53
A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care (2010) 1.50
Basal-prandial insulin delivery in type 2 diabetes mellitus via the V-Go: a novel continuous subcutaneous infusion device. J Diabetes Sci Technol (2008) 1.46
Response to Swinnen et al. Diabetes Technol Ther (2010) 1.39
Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab (2009) 1.31
Insulin therapy for type 2 diabetes. Diabetes Care (2009) 1.23
Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study. Diabetes Care (2013) 1.19
Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res (2008) 1.17
Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol (2011) 1.12
Uncovering undetected hypoglycemic events. Diabetes Metab Syndr Obes (2012) 1.07
Hypoglycemia: The neglected complication. Indian J Endocrinol Metab (2013) 1.01
How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract (2010) 1.01
Common standards of basal insulin titration in type 2 diabetes. J Diabetes Sci Technol (2013) 0.99
The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes. J Diabetes Sci Technol (2008) 0.99
Identifying and meeting the challenges of insulin therapy in type 2 diabetes. J Multidiscip Healthc (2014) 0.98
The median is not the only message: a clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus. J Diabetes Sci Technol (2009) 0.97
Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease. Vasc Health Risk Manag (2008) 0.96
Diabetes care - insulin delivery in a changing world. Medscape J Med (2008) 0.96
Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas. Diabetes Care (2012) 0.95
Safety and efficacy of modern insulin analogues. Diabetes Metab J (2013) 0.95
Insulin therapy and hypoglycemia. Endocrinol Metab Clin North Am (2012) 0.95
A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes. J Matern Fetal Neonatal Med (2013) 0.91
An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog. Vasc Health Risk Manag (2010) 0.90
A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes. Osteopath Med Prim Care (2007) 0.90
Nocturnal hypoglycemia: answering the challenge with long-acting insulin analogs. MedGenMed (2007) 0.89
Common crossroads in diabetes management. Osteopath Med Prim Care (2008) 0.86
Initiating insulin in patients with type 2 diabetes. CMAJ (2012) 0.86
Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial. Diabet Med (2013) 0.86
Metabolic effects of Basal or premixed insulin treatment in 5077 insulin-naïve type 2 diabetes patients: registry-based observational study in clinical practice. Diabetes Ther (2014) 0.85
Optimal therapy of type 2 diabetes: a controversial challenge. Aging (Albany NY) (2014) 0.85
Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus. Diabetes Care (2011) 0.85
Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. Diabetes Care (2009) 0.85
Diabetes screening, diagnosis, and therapy in pediatric patients with type 2 diabetes. Medscape J Med (2008) 0.85
Basal insulin analogues in the treatment of diabetes mellitus: What progress have we made? Indian J Endocrinol Metab (2015) 0.84
Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther (2010) 0.84
Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice. Scand J Prim Health Care (2007) 0.84
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Front Immunol (2015) 0.84
Treat-to-target trials: uses, interpretation and review of concepts. Diabetes Obes Metab (2013) 0.84
Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. MedGenMed (2007) 0.83
Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study. Pharmacoepidemiol Drug Saf (2013) 0.82
Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab (2015) 0.82
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in type 2 diabetes. Diabetes Care (2011) 0.82
Management of diabetes across the course of disease: minimizing obesity-associated complications. Diabetes Metab Syndr Obes (2011) 0.82
Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control. Minerva Endocrinol (2013) 0.81
Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes. Diabetologia (2009) 0.81
Detemir as a once-daily basal insulin in type 2 diabetes. Clin Pharmacol (2011) 0.81
Initiating or switching to biphasic insulin aspart 30/70 therapy in subjects with type 2 diabetes mellitus. An observational study. Rev Diabet Stud (2008) 0.81
Insulin Detemir Is Transported From Blood to Cerebrospinal Fluid and Has Prolonged Central Anorectic Action Relative to NPH Insulin. Diabetes (2015) 0.81
Diabetes management: optimizing roles for nurses in insulin initiation. J Multidiscip Healthc (2011) 0.80
Analog insulin detemir for patients with type 1 and type 2 diabetes: a review. Diabetes Metab Syndr Obes (2009) 0.80
Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. Int J Clin Pract (2012) 0.80
Clinical experience with insulin detemir in patients with type 2 diabetes from the near East countries. Diabetes Ther (2013) 0.79
Insulin detemir for the treatment of obese patients with type 2 diabetes. Diabetes Metab Syndr Obes (2012) 0.79
Tolerability, safety and adherence to treatment with insulin detemir injection in the treatment of type 2 diabetes. Patient Prefer Adherence (2008) 0.79
Insulin detemir attenuates food intake, body weight gain and fat mass gain in diet-induced obese Sprague-Dawley rats. Nutr Diabetes (2011) 0.79
Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analyses. J Diabetes Investig (2012) 0.79
Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational study. Diabetol Metab Syndr (2013) 0.79
Pursuit of a perfect insulin. Nat Rev Drug Discov (2016) 0.78
3-Month Results from Denmark within the Globally Prospective and Observational Study to Evaluate Insulin Detemir Treatment in Type 1 and Type 2 Diabetes: The PREDICTIVE Study. Rev Diabet Stud (2007) 0.78
Diabetes: glycaemic control in type 2 (drug treatments). BMJ Clin Evid (2012) 0.78
Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes. J Clin Med Res (2016) 0.78
Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia. Vasc Health Risk Manag (2009) 0.78
Comparison of thrice-daily lispro 50/50 vs thrice-daily lispro in combination with sulfonylurea as initial insulin therapy for type 2 diabetes. J Diabetes Investig (2010) 0.78
Treatment intensification using long-acting insulin -predictors of future basal insulin supported oral therapy in the DIVE registry. BMC Endocr Disord (2015) 0.78
Insulin detemir enhances proglucagon gene expression in the intestinal L cells via stimulating β-catenin and CREB activities. Am J Physiol Endocrinol Metab (2012) 0.77
Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes. Diabetes Obes Metab (2014) 0.77
Overcoming barriers to glycemic control in African Americans with type-2 diabetes: benefits of insulin therapy. J Natl Med Assoc (2007) 0.77
New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs. J Natl Med Assoc (2007) 0.77
Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients. BMC Endocr Disord (2012) 0.77
Clinical experience of switching from glargine or neutral protamine Hagedorn insulin to insulin detemir in type 2 diabetes: Observations from the Indian cohort in the A1chieve study. Indian J Endocrinol Metab (2014) 0.77
Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis. BMJ Open (2016) 0.77
Treating the elderly diabetic patient: special considerations. Diabetes Metab Syndr Obes (2014) 0.77
Type 2 diabetes mellitus management and body mass index: experiences with initiating insulin detemir in the a1chieve study. Diabetes Ther (2014) 0.76
Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes. CADTH Technol Overv (2010) 0.76
Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics. Diabetes Metab Syndr Obes (2010) 0.76
Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial. Diabetes Obes Metab (2013) 0.76
The role of insulin detemir in overweight type 2 diabetes management. Vasc Health Risk Manag (2009) 0.76
[The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus]. Wien Klin Wochenschr (2009) 0.76
Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry. BMJ Open Diabetes Res Care (2017) 0.75
Insulin Detemir in Combination with Oral Antidiabetic Drugs Improves Glycemic Control in Persons with Type 2 Diabetes in Near East Countries: Results from the Lebanese Subgroup. Ethn Dis (2017) 0.75
Cardiovascular effects of basal insulins. Drug Healthc Patient Saf (2015) 0.75
Safety and effectiveness of insulin detemir in different age-groups in the a1chieve study. Diabetes Ther (2013) 0.75
Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain. Diabetes Ther (2015) 0.75
Clinical considerations for insulin pharmacotherapy in ambulatory care, part two: review of primary literature and an evidence-based approach for treatment. Clin Diabetes (2015) 0.75
Clinical utility of insulin and insulin analogs. Islets (2013) 0.75
Effects of Age on Glycemic Control in Patients With Type 2 Diabetes Treated with Insulin Detemir: A Post-Hoc Analysis of the PREDICTIVE™ 303 Study. Drugs Aging (2016) 0.75
Trends in Emergency Department Visit Rates for Hypoglycemia and Hyperglycemic Crisis among Adults with Diabetes, United States, 2006-2011. PLoS One (2015) 0.75
Which career first? BMJ (2005) 4.34
Cancer risk among children born after assisted conception. N Engl J Med (2013) 3.36
Modernising medical careers, medical training application service, and the postgraduate medical education and training board: time for the emperors to don their clothes. Lancet (2007) 3.12
A critical review of the literature on fear of hypoglycemia in diabetes: Implications for diabetes management and patient education. Patient Educ Couns (2007) 2.42
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther (2006) 2.41
Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation (2004) 2.16
Should we screen for type 2 diabetes: Yes. BMJ (2012) 2.13
Type 2 diabetes and cardiovascular disease in South Asians. Prim Care Diabetes (2010) 1.78
The association between depression and health-related quality of life in people with type 2 diabetes: a systematic literature review. Diabetes Metab Res Rev (2010) 1.66
Effectiveness of a pragmatic education program designed to promote walking activity in individuals with impaired glucose tolerance: a randomized controlled trial. Diabetes Care (2009) 1.61
Flexible training under the new deal. BMJ (2002) 1.58
Diabetes Attitudes Wishes and Needs 2 (DAWN2): a multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care. Diabetes Res Clin Pract (2012) 1.57
Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care (2013) 1.55
Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care (2007) 1.50
A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care (2010) 1.50
Unanswered questions over NHS health checks. BMJ (2010) 1.22
Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update (2004) 1.21
Influences on the uptake of diabetes screening: a qualitative study in primary care. Br J Gen Pract (2012) 1.20
Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther (2011) 1.14
Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig (2007) 1.11
Malignant melanoma presenting as a foot ulcer. Lancet (2005) 1.07
Safety of very tight blood glucose control in type 2 diabetes. BMJ (2008) 1.07
Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care (2012) 1.04
Rationale, design and baseline data from the Pre-diabetes Risk Education and Physical Activity Recommendation and Encouragement (PREPARE) programme study: a randomized controlled trial. Patient Educ Couns (2008) 1.01
The National Institute of Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) for Leicestershire, Northamptonshire and Rutland (LNR): a programme protocol. Implement Sci (2009) 1.01
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol (2014) 1.01
Medical training in the UK: sleepwalking to disaster. Lancet (2007) 0.99
Waiting for diabetes: perceptions of people with pre-diabetes: a qualitative study. Patient Educ Couns (2008) 0.98
Predicting the development of macrovascular disease in people with type 1 diabetes: A 9-year follow-up study. Ann N Y Acad Sci (2006) 0.98
Characteristics, complications and management of a large multiethnic cohort of younger adults with type 2 diabetes. Prim Care Diabetes (2011) 0.98
Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther (2008) 0.95
Primary prevention of cardiovascular disease using validated risk scores: a systematic review. J R Soc Med (2012) 0.92
Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. J Am Geriatr Soc (2007) 0.91
Should A1C targets be individualized for all people with diabetes? Arguments for and against. Diabetes Care (2011) 0.91
Metabolic syndrome. BMJ (2005) 0.89
Standardisation of glycated haemoglobin. BMJ (2004) 0.84
Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. Curr Med Res Opin (2010) 0.83
Preventing type 2 diabetes: making the evidence work for migrant Indian populations. Indian J Med Res (2009) 0.83
Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System. Br J Clin Pharmacol (2005) 0.83
Cardiovascular risk factors predicting the development of distal symmetrical polyneuropathy in people with type 1 diabetes: A 9-year follow-up study. Ann N Y Acad Sci (2006) 0.82
Pulmonary insulin administration using the AERx insulin diabetes system. Diabetes Technol Ther (2002) 0.81
Type 2 diabetes in younger adults: clinical characteristics, diabetes-related complications and management of risk factors. Prim Care Diabetes (2010) 0.81
Improving metabolic control in sub-optimally controlled subjects with Type 1 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Res Clin Pract (2006) 0.81
Walking and inflammatory markers in individuals screened for type 2 diabetes. Prev Med (2008) 0.80
A review of exenatide: optimizing glycemic control and associated cardiovascular risk factors in type 2 diabetes. Diabetes Ther (2012) 0.78
Diabetes: glycaemic control in type 2. BMJ Clin Evid (2008) 0.78
Biphasic insulin aspart 30 in insulin-naive people with type 2 diabetes in non-western nations: results from a regional comparative multinational observational study (A(1)chieve). Diabetes Technol Ther (2013) 0.77
Nonexercise Equations to Estimate Fitness in White European and South Asian Men. Med Sci Sports Exerc (2016) 0.77
Sedentary Sphere: Wrist-Worn Accelerometer-Brand Independent Posture Classification. Med Sci Sports Exerc (2016) 0.77
Raw Accelerometer Data Analysis with GGIR R-package: Does Accelerometer Brand Matter? Med Sci Sports Exerc (2016) 0.77
The impact of large tidal volume ventilation on the absorption of inhaled insulin in rabbits. Eur J Pharm Sci (2006) 0.76
Preservation of fertility in women undergoing reduced-intensity conditioning allogeneic transplantation with a fludarabine-based regime. Transplantation (2012) 0.76
Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): good for sulfonylureas? Diabetes Care (2007) 0.75
The effect of exercise on the absorption of inhaled human insulin in healthy volunteers. Br J Clin Pharmacol (2007) 0.75
Authors' response. Br J Gen Pract (2013) 0.75
Diabetes: glycaemic control in type 1. BMJ Clin Evid (2008) 0.75
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics (2007) 0.75
A Text-Messaging and Pedometer Program to Promote Physical Activity in People at High Risk of Type 2 Diabetes: The Development of the PROPELS Follow-On Support Program. JMIR Mhealth Uhealth (2015) 0.75
British Fertility Society. 'Ovulation induction in WHO Type 1 anovulation: Guidelines for practice'. Produced on behalf of the BFS Policy and Practice Committee. Hum Fertil (Camb) (2013) 0.75
Observational research: an integral part of enhancing diabetes management in south-east Asia. Diabetes Res Clin Pract (2013) 0.75
The 'Girls Active' Physical Activity Intervention: Baseline Characteristics Of Objectively Measured Physical Activity: 3215 Board #280 June 3, 2: 00 PM - 3: 30 PM. Med Sci Sports Exerc (2016) 0.75
The effect of exercise on the absorption of inhaled human insulin via the AERx insulin diabetes management system in people with type 1 diabetes. Diabetes Care (2007) 0.75
Tight control of blood glucose and cardiovascular disease. BMJ (2008) 0.75
Accelerometer-assessed Physical Activity in Epidemiology: Are Monitors Equivalent? Med Sci Sports Exerc (2017) 0.75